Cargando…
Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country
INTRODUCTION: Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the Malaysia...
Autores principales: | How, Soon Hin, Tho, Lye Mun, Liam, Chong Kin, Hasbullah, Harissa H., Ho, Gwo Fuang, Muhammad Nor, Ibtisam, Poh, Mau Ern, Ho, Kean Fatt, Thiagarajan, Muthukkumaran, Samsudin, Azlina, Omar, Azza, Ong, Choo Khoon, Pang, Yong Kek, Soon, Sing Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161340/ https://www.ncbi.nlm.nih.gov/pubmed/35502623 http://dx.doi.org/10.1111/1759-7714.14442 |
Ejemplares similares
-
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
por: Poh, Mau Ern, et al.
Publicado: (2023) -
Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
por: How, Soon Hin, et al.
Publicado: (2022) -
Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Chai, Chee-Shee, et al.
Publicado: (2020) -
Endobronchial metastasis from resected renal cell carcinoma causing total lung collapse
por: Poh, Mau-Ern, et al.
Publicado: (2013) -
Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)